Toronto Dominion Bank Purchases 105,671 Shares of Tilray Inc (NASDAQ:TLRY)

Toronto Dominion Bank increased its position in Tilray Inc (NASDAQ:TLRY) by 454.5% during the third quarter, according to its most recent Form 13F filing with the SEC. The fund owned 128,923 shares of the company’s stock after buying an additional 105,671 shares during the period. Toronto Dominion Bank’s holdings in Tilray were worth $227,000 at the end of the most recent reporting period.

Several other hedge funds and other institutional investors have also recently added to or reduced their stakes in the business. Barclays PLC increased its stake in shares of Tilray by 600.4% during the 3rd quarter. Barclays PLC now owns 204,144 shares of the company’s stock worth $359,000 after purchasing an additional 174,997 shares during the last quarter. XTX Topco Ltd increased its position in Tilray by 1,079.7% during the third quarter. XTX Topco Ltd now owns 281,504 shares of the company’s stock worth $495,000 after buying an additional 257,641 shares during the last quarter. State Street Corp increased its position in Tilray by 4.7% during the third quarter. State Street Corp now owns 1,961,338 shares of the company’s stock worth $3,452,000 after buying an additional 88,079 shares during the last quarter. Point72 Asset Management L.P. bought a new position in Tilray during the third quarter valued at about $1,348,000. Finally, UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC lifted its position in shares of Tilray by 6.8% in the third quarter. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC now owns 1,677,899 shares of the company’s stock worth $2,953,000 after buying an additional 107,530 shares during the last quarter. Institutional investors own 9.35% of the company’s stock.

Insiders Place Their Bets

In related news, CFO Carl A. Merton purchased 26,000 shares of the firm’s stock in a transaction on Friday, November 15th. The shares were bought at an average cost of $1.36 per share, for a total transaction of $35,360.00. Following the transaction, the chief financial officer now directly owns 26,000 shares of the company’s stock, valued at approximately $35,360. This trade represents a ∞ increase in their position. The transaction was disclosed in a legal filing with the SEC, which is accessible through the SEC website. Company insiders own 0.87% of the company’s stock.

Analyst Ratings Changes

Separately, Roth Mkm cut their price objective on Tilray from $2.00 to $1.75 and set a “neutral” rating on the stock in a research note on Friday, October 11th.

Tilray Stock Performance

NASDAQ:TLRY opened at $1.20 on Tuesday. The firm has a market capitalization of $1.08 billion, a PE ratio of -4.44 and a beta of 2.08. Tilray Inc has a 1 year low of $1.15 and a 1 year high of $2.97. The company has a current ratio of 2.47, a quick ratio of 1.57 and a debt-to-equity ratio of 0.08. The firm’s fifty day simple moving average is $1.48 and its 200 day simple moving average is $1.67.

Tilray (NASDAQ:TLRY) last issued its quarterly earnings results on Thursday, October 10th. The company reported ($0.04) earnings per share (EPS) for the quarter, meeting the consensus estimate of ($0.04). Tilray had a negative return on equity of 2.00% and a negative net margin of 26.79%. The company had revenue of $200.00 million for the quarter, compared to the consensus estimate of $218.70 million. During the same period last year, the business posted ($0.10) earnings per share. The firm’s revenue was up 13.0% compared to the same quarter last year. On average, sell-side analysts anticipate that Tilray Inc will post -0.14 EPS for the current year.

Tilray Profile

Tilray, Inc engages in the research, cultivation, processing, and distribution of medical cannabis. The company offers its products in Argentina, Australia, Canada, Chile, Croatia, Cyprus, the Czech Republic, Germany, New Zealand, and South Africa. Tilray, Inc is headquartered in Canada.